Located in the newly opened - June 2018 - Tokyo Headquarters, Philippe leads the regional and cross-functional medical team dedicated to specialty medicines.
For years, Takeda Pharmaceuticals has put the patient at the center of its priorities and philosophy. In his current role, Philippe daily cares that the patient perspectives, needs, and priorities are optimally integrate in strategy and tactics for specialty medicines development, registration and market access. This means a particular attention to real world evidence data generation and patient reported outcomes usages but not only.
Philippe joined Takeda Pharmaceuticals in October 2016 as Country Medical Director of the Korean subsidiary. Philippe has about 20 years of successful experiences in management, including matrix and international teams, and in drugs development and registration. Prior joining Takeda Pharmaceuticals, Philippe has worked in several multinational pharmaceutical companies as Eli Lilly Company, Novartis, Celgene and Leo, in different locations (Europe, USA and JAPAC) and with either local or regional or global responsibilities.
In his two years in Seoul, Philippe has favorably reshaped and rebooted the Korean Medical Team to act and to be recognized as a highly competent and reliable partner by its internal and external stakeholders, leveraging on the strong patient centric Takeda philosophy.
Philippe has earned a medical degree (MD) with specialties in Cardiology and Intensive Care (PhD) from the Universities of Lille and Paris (France) and an Executive MBA from HEC (Paris, France). After his MD and PhD graduations, and prior joining the pharmaceutical industry, Philippe has been a hospital practitioner within the resuscitation ward of a University hospital (France).